Asset Details
Do you wish to reserve the book?
In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy
Do you wish to request the book?
In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy
2024
Overview
Immune checkpoint blockade (ICB) therapy, while promising for cancer treatment, faces challenges like unexpected side effects and limited objective responses. Here, we develop an in vivo gene-editing strategy for improving ICB cancer therapy in a lastingly effective manner. The approach uses a conductive hydrogel-based electroporation system to enable nucleofection of programmed cell death protein 1 (PD1) targeted CRISPR-Cas9 DNAs into T-cells directly within the lymph nodes, and subsequently produces PD1-deficient T-cells to combat tumor growth, metastasis and recurrence in different melanoma models in mice. Following in vivo gene editing, animals show enhanced cellular and humoral immune responses along with multi-fold increases of effector T-cells infiltration to the solid tumors, preventing tumor recurrence and prolonging their survival. These findings provide a proof-of-concept for direct in vivo T-cell engineering via localized gene-editing for enhanced cancer immunotherapy, and also unlock the possibilities of using this method to treat more complex human diseases.
As an alternative to the systemic delivery of immune checkpoint inhibitors, here the authors develop an in vivo gene-edit strategy using a conductive hydrogel-based electroporation system to enable nucleofection of PD1-targeted CRISPR-Cas9 DNAs into lymph node T-cells, resulting in suppression of PD1 expression and promotion of anti-tumor immune responses in preclinical cancer models.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 38/1
/ 38/39
/ 42/109
/ 9/10
/ Animals
/ Cancer
/ CRISPR
/ CRISPR-Cas Systems - genetics
/ Editing
/ Female
/ Humanities and Social Sciences
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - pharmacology
/ Immune Checkpoint Inhibitors - therapeutic use
/ Melanoma
/ Melanoma, Experimental - genetics
/ Melanoma, Experimental - immunology
/ Melanoma, Experimental - therapy
/ Mice
/ Programmed Cell Death 1 Receptor - antagonists & inhibitors
/ Programmed Cell Death 1 Receptor - genetics
/ Programmed Cell Death 1 Receptor - metabolism
/ Science
/ Tumors
